Literature DB >> 21463374

Irinotecan-induced alterations in intestinal cell kinetics and extracellular matrix component expression in the Dark Agouti rat.

Noor Al-Dasooqi1, Joanne M Bowen, Rachel J Gibson, Richard M Logan, Andrea M Stringer, Dorothy M Keefe.   

Abstract

Chemotherapy-induced mucositis is characterized by damage of mucous membranes throughout the alimentary tract (AT). Extracellular matrix (ECM) components play a vital role in maintaining mucosal barrier integrity by regulating cellular apoptosis, proliferation and differentiation of overlying epithelial cells. The aims of this study were to characterize the changes in epithelial cell kinetics and to investigate the expression of the ECM components in the gastrointestinal tract following irinotecan administration. Female dark agouti rats were treated with single 200 mg/kg dose irinotecan and killed at various time points (1, 6, 24, 48, 72, 96 and 14 h) after treatment. Ki67 immunostaining and TUNEL were used to assess proliferation and apoptosis, respectively, in the jejunum and colon. Masson trichrome staining and picro-sirius red staining were used to determine the level of collagen, and immunohistochemistry was used to further assess collagen IV, fibronectin and laminin 1 and 2 expression in these tissues. Irinotecan halved cellular proliferation in the jejunum and colon at 48 and 24 h, respectively, while apoptosis peaked at 6 h (P < 0.05). There was a substantial increase in total collagen deposits around crypts from 24 h in both regions. However, collagen IV expression decreased significantly in the crypt region in a delayed fashion (P < 0.05). Fibronectin expression decreased significantly in jejunum and colon from 6 to 24 h following treatment (P < 0.05). Irinotecan induced a significant alteration in epithelial cell kinetics in both the jejunum and colon, and this correlated with changes in ECM component expression. Changes in ECM expression may have a direct impact on the loss of mucosal layer integrity evident in chemotherapy-induced mucositis.
© 2011 The Authors. International Journal of Experimental Pathology © 2011 International Journal of Experimental Pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21463374      PMCID: PMC3193150          DOI: 10.1111/j.1365-2613.2011.00771.x

Source DB:  PubMed          Journal:  Int J Exp Pathol        ISSN: 0959-9673            Impact factor:   1.925


  33 in total

Review 1.  The pathobiology of mucositis.

Authors:  Stephen T Sonis
Journal:  Nat Rev Cancer       Date:  2004-04       Impact factor: 60.716

Review 2.  Extracellular matrix components and integrins in relationship to human intestinal epithelial cell differentiation.

Authors:  J F Beaulieu
Journal:  Prog Histochem Cytochem       Date:  1997

3.  Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat.

Authors:  Noor Al-Dasooqi; Rachel J Gibson; Joanne M Bowen; Richard M Logan; Andrea M Stringer; Dorothy M Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2010-08-03

4.  Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice.

Authors:  F Paris; Z Fuks; A Kang; P Capodieci; G Juan; D Ehleiter; A Haimovitz-Friedman; C Cordon-Cardo; R Kolesnick
Journal:  Science       Date:  2001-07-13       Impact factor: 47.728

5.  Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters.

Authors:  S T Sonis; R L Peterson; L J Edwards; C A Lucey; L Wang; L Mason; G Login; M Ymamkawa; G Moses; P Bouchard; L L Hayes; C Bedrosian; A J Dorner
Journal:  Oral Oncol       Date:  2000-07       Impact factor: 5.337

6.  Changes in epithelial cell turnover and extracellular matrix in human small intestine after TPN.

Authors:  Stephanie Groos; Enrico Reale; Günter Hünefeld; Liliana Luciano
Journal:  J Surg Res       Date:  2003-02       Impact factor: 2.192

Review 7.  Lessons learned from the irinotecan metabolic pathway.

Authors:  M K Ma; H L McLeod
Journal:  Curr Med Chem       Date:  2003-01       Impact factor: 4.530

Review 8.  Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients.

Authors:  Stephen T Sonis; Linda S Elting; Dorothy Keefe; Douglas E Peterson; Mark Schubert; Martin Hauer-Jensen; B Nebiyou Bekele; Judith Raber-Durlacher; J Peter Donnelly; Edward B Rubenstein
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

9.  Irinotecan causes severe small intestinal damage, as well as colonic damage, in the rat with implanted breast cancer.

Authors:  Rachel J Gibson; Joanne M Bowen; Mark R B Inglis; Adrian G Cummins; Dorothy M K Keefe
Journal:  J Gastroenterol Hepatol       Date:  2003-09       Impact factor: 4.029

10.  The extracellular matrix as a cell survival factor.

Authors:  J E Meredith; B Fazeli; M A Schwartz
Journal:  Mol Biol Cell       Date:  1993-09       Impact factor: 4.138

View more
  17 in total

1.  Fractionated abdominal irradiation induces intestinal microvascular changes in an in vivo model of radiotherapy-induced gut toxicity.

Authors:  Romany L Stansborough; Emma H Bateman; Noor Al-Dasooqi; Joanne M Bowen; Dorothy M K Keefe; Ann S J Yeoh; Richard M Logan; Eric E K Yeoh; Andrea M Stringer; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2017-02-07       Impact factor: 3.603

Review 2.  Gastrointestinal mucositis: the role of MMP-tight junction interactions in tissue injury.

Authors:  Noor Al-Dasooqi; Hannah R Wardill; Rachel J Gibson
Journal:  Pathol Oncol Res       Date:  2014-01-15       Impact factor: 3.201

3.  Selective MMP Inhibition, Using AZD3342, to Reduce Gastrointestinal Toxicity and Enhance Chemoefficacy in a Rat Model.

Authors:  Rachel J Gibson; Ysabella Z A van Sebille; Hannah R Wardill; Anthony Wignall; Joseph Shirren; Imogen A Ball; Nicole Williams; Kiara Wanner; Joanne M Bowen
Journal:  Chemotherapy       Date:  2019-02-07       Impact factor: 2.544

4.  Effect of irinotecan on the tongue mucosa of juvenile male albino rat at adulthood.

Authors:  Marwa Awad Abdel Hamid Ibrahim; Walaa M Elwan
Journal:  Int J Exp Pathol       Date:  2019-10-02       Impact factor: 1.925

Review 5.  Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.

Authors:  Barbara Vanhoecke; Emma Bateman; Bronwen Mayo; Eline Vanlancker; Andrea Stringer; Daniel Thorpe; Dorothy Keefe
Journal:  Exp Biol Med (Maywood)       Date:  2015-05-12

6.  Cell adhesion molecules are altered during irinotecan-induced mucositis: a qualitative histopathological study.

Authors:  Noor Al-Dasooqi; Joanne Bowen; Colin Bennett; John Finnie; Dorothy Keefe; Rachel Gibson
Journal:  Support Care Cancer       Date:  2016-09-20       Impact factor: 3.603

Review 7.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-04-21       Impact factor: 3.603

8.  Tight junction defects are seen in the buccal mucosa of patients receiving standard dose chemotherapy for cancer.

Authors:  Hannah R Wardill; Richard M Logan; Joanne M Bowen; Ysabella Z A Van Sebille; Rachel J Gibson
Journal:  Support Care Cancer       Date:  2015-10-06       Impact factor: 3.603

Review 9.  Emerging evidence on the pathobiology of mucositis.

Authors:  Noor Al-Dasooqi; Stephen T Sonis; Joanne M Bowen; Emma Bateman; Nicole Blijlevens; Rachel J Gibson; Richard M Logan; Raj G Nair; Andrea M Stringer; Roger Yazbeck; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-07-11       Impact factor: 3.603

10.  Perturbations in Endocytotic and Apoptotic Pathways Are Associated With Chemotherapy-Induced Nausea.

Authors:  Komal Singh; Huangshen Cao; Christine Miaskowski; Yvette P Conley; Marilyn Hammer; Fay Wright; Jon D Levine; Kord M Kober
Journal:  Biol Res Nurs       Date:  2020-08-20       Impact factor: 2.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.